These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 22872694)

  • 1. Pharmaceutical research and development: what do we get for all that money?
    Light DW; Lexchin JR
    BMJ; 2012 Aug; 345():e4348. PubMed ID: 22872694
    [No Abstract]   [Full Text] [Related]  

  • 2. Can emerging drug classes improve R&D productivity?
    Meier C; Cairns-Smith S; Schulze U
    Drug Discov Today; 2013 Jul; 18(13-14):607-9. PubMed ID: 23702084
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug development: Innovation or imitation deficit?
    Morgan SG; Cunningham CM; Law MR
    BMJ; 2012 Sep; 345():e5880. PubMed ID: 22951558
    [No Abstract]   [Full Text] [Related]  

  • 4. [Dismantling of "Big Pharma" gives new impetus to the pharmaceutical sector. Dynamic life science clusters can increase Swedish competitiveness].
    Hedner T; Gatenbeck L
    Lakartidningen; 2012 Jun 27-Jul 17; 109(26-28):1280-1. PubMed ID: 22852257
    [No Abstract]   [Full Text] [Related]  

  • 5. Precompetitive research: a new prescription for drug development?
    Woodcock J
    Clin Pharmacol Ther; 2010 May; 87(5):521-3. PubMed ID: 20407454
    [No Abstract]   [Full Text] [Related]  

  • 6. The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplace.
    Sollano JA; Kirsch JM; Bala MV; Chambers MG; Harpole LH
    Clin Pharmacol Ther; 2008 Aug; 84(2):263-6. PubMed ID: 18547999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. David Haslam. Interview by Asher Mullard.
    Haslam D
    Nat Rev Drug Discov; 2013 Jul; 12(7):500. PubMed ID: 23764976
    [No Abstract]   [Full Text] [Related]  

  • 8. An assessment of R&D productivity in the pharmaceutical industry.
    Dimitri N
    Trends Pharmacol Sci; 2011 Dec; 32(12):683-5. PubMed ID: 22030299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New blood: Creative funding of disease-specific research.
    Seaman WE; Locksley RM; Welsh MJ
    Sci Transl Med; 2015 May; 7(288):288ed5. PubMed ID: 25995219
    [No Abstract]   [Full Text] [Related]  

  • 10. US drug manufacturers set up joint testing group.
    Davies E
    BMJ; 2012 Sep; 345():e6394. PubMed ID: 23002149
    [No Abstract]   [Full Text] [Related]  

  • 11. Using patent data to assess the value of pharmaceutical innovation.
    Kesselheim AS; Avorn J
    J Law Med Ethics; 2009; 37(2):176-83. PubMed ID: 19493065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new prize system for drug innovation.
    Gandjour A; Chernyak N
    Health Policy; 2011 Oct; 102(2-3):170-7. PubMed ID: 21724290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A dynamic perspective on pharmaceutical competition, drug development and cost effectiveness.
    Refoios Camejo R; McGrath C; Herings R
    Health Policy; 2011 Apr; 100(1):18-24. PubMed ID: 20864202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Torching the Haystack: modelling fast-fail strategies in drug development.
    Lendrem DW; Lendrem BC
    Drug Discov Today; 2013 Apr; 18(7-8):331-6. PubMed ID: 23246516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rewarding innovation in drug discovery.
    Lopes G
    Health Aff (Millwood); 2009; 28(3):922-3. PubMed ID: 19414906
    [No Abstract]   [Full Text] [Related]  

  • 16. [Going from research to development: which support and financing tools?].
    Roques S
    Presse Med; 2012 May; 41 Suppl 1():S43-5. PubMed ID: 22465719
    [No Abstract]   [Full Text] [Related]  

  • 17. Defining innovation.
    Hughes B
    Nat Rev Drug Discov; 2009 Sep; 8(9):683-4. PubMed ID: 19721435
    [No Abstract]   [Full Text] [Related]  

  • 18. Open innovation: the new face of pharmaceutical research and development.
    Getz KA; Kaitin KI
    Expert Rev Clin Pharmacol; 2012 Sep; 5(5):481-3. PubMed ID: 23121265
    [No Abstract]   [Full Text] [Related]  

  • 19. The 10 x '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020.
    Infectious Diseases Society of America
    Clin Infect Dis; 2010 Apr; 50(8):1081-3. PubMed ID: 20214473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are predictive biomarkers of toxicity worth having? An economic model.
    Jones B; Smith DA; Schmid EF
    Xenobiotica; 2012 Jan; 42(1):4-10. PubMed ID: 21970747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.